Curated News
By: NewsRamp Editorial Staff
July 30, 2026

HeartBeam to Report Q2 2026 Earnings on Aug 13

Discuss on Substack Discuss on Telegram View History of this news story on GitHub
Original Source

TLDR

  • HeartBeam's FDA-cleared 3D ECG platform positions it ahead in portable cardiac monitoring, offering a competitive edge for early investors.
  • HeartBeam synthesizes 3D ECG signals into a 12-lead ECG using a cable-free device, with FDA clearance for arrhythmia assessment.
  • HeartBeam's portable ECG technology enables cardiac monitoring outside hospitals, improving access to care and potentially saving lives.
  • The system is the first cable-free device to collect 3D ECG signals from three directions, redefining heart health management.

Impact - Why it Matters

This news matters because HeartBeam's ambulatory ECG platform could revolutionize cardiac care by enabling continuous, remote monitoring of heart conditions. For patients, this means earlier detection of arrhythmias and other cardiac issues without the need for hospital visits, potentially saving lives and reducing healthcare costs. For investors, the company's progress in FDA clearances and patent portfolio signals strong growth potential in the medtech sector, making this update crucial for assessing the company's trajectory.

Summary

HeartBeam (NASDAQ: BEAT), a medical technology company focused on cardiac care, is set to host a conference call on August 13 at 4:30 p.m. ET to discuss its second-quarter 2026 financial results and provide updates on its strategy to accelerate global adoption of its ambulatory ECG signal platform. The call will be led by Executive Chairman Richard Ferrari, President and Founder Branislav Vajdic, and CFO Timothy Cruickshank, featuring prepared remarks followed by a Q&A session. This announcement underscores HeartBeam's commitment to advancing cardiac detection and monitoring through innovative technology.

HeartBeam is pioneering the first cable-free device capable of collecting ECG signals in 3D from three non-coplanar directions and synthesizing them into a 12-lead ECG. This platform is designed for portable use, delivering actionable heart intelligence outside medical facilities. The company's 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, and its 12-lead ECG synthesis software gained clearance in December 2025. With over 20 issued patents, HeartBeam aims to redefine cardiac health management by enabling physicians to identify trends and acute conditions remotely.

The full press release is available at the provided link, and investors can access the latest news on BEAT through the company's newsroom. This development is particularly significant given the growing demand for remote patient monitoring solutions. HeartBeam's technology addresses a critical need in cardiac care, offering a non-invasive, portable alternative to traditional ECG systems, potentially reducing hospital visits and improving patient outcomes. The conference call will likely provide deeper insights into the company's market penetration and future growth plans.

Source Statement

This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, HeartBeam to Report Q2 2026 Earnings on Aug 13

blockchain registration record for this content.